Oxapex® (also known as Oxmax® in EU & UK) 
Hemoglobin betafumaril (bovine)
PRODUCTS
Oxapex® (also known as Oxmax® in EU & UK)
Hemoglobin betafumaril (bovine)

Oxapex® is a highly purified and stabilized haemoglobin solution which enhances oxygen transport and improves tissue oxygenation by increasing systemic plasma haemoglobin concentration in anaemic dogs1,2.

Each millilitre (mL) of Oxapex® contains 65mg hemoglobin betafumaril (bovine), obtained from cattle in New Zealand, a country with a negligible risk for Bovine Spongiform Encephalopathy.

The unique features of Oxapex®, including rapid restoration of tissue oxygenation, readiness of administration and convenient storage, enable it to be used extensively in clinical settings.

The product is supplied in infusion bag. The bag is overwrapped with an aluminium pouch, and is packed into a cardboard box. Each cardboard box contains 2 bags of 100mL.

Oxapex® is a veterinary prescription medicine registered in New Zealand for use in dogs. ACVM Registration No. A010809.

Oxapex® is INDEXED by US FDA for the use in captive mustelids, captive rodents, raptors, and captive or pet birds of the orders Psittaciformes, Passeriformes, and Columbiformes.
LEGAL STATUS—In order to be legally marketed, a new animal drug intended for a minor species must be Approved, Conditionally Approved, or Indexed by the Food and Drug Administration. THIS PRODUCT IS INDEXED—MIF #900-018.

Oxmax®, the registered trade name of Oxapex® in EU, received a positive opinion by EMA/CVMP in September 2023. The European Commission has granted the Marketing Authorization for Oxmax® on 19 Oct 2023. It is indicated as an adjunct therapy in the management of haemorrhagic shock in dogs.

Oxmax®, the registered trade name of Oxapex® in UK,  was recommended for approval by VMD for its marketing authorization application in October 2023.

For further information, please go to www.oxapex.com or contact New Alpha Innovation Limited:
Email: newaiinfo@newalphainnovation.com

References:
1. Data on file.
2. Oxapex® prescribing information. New Alpha Innovation New Zealand Limited. Version 2020.

 

 

 

 

× We use page tagging techniques and cookies to improve the site, provide services to you, and customize your browsing experience. By continuing to browse the site you are agreeing to accept our use of cookies